Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

Abstract

Although the tyrosine kinase inhibitor (TKI) era has brought great improvement in outcome in chronic myelogenous leukemia (CML), prognosis of accelerated phase or myeloid blast crisis patients or of de novo Philadelphia chromosome-positive acute myeloid leukemia remains poor. We conducted a retrospective study on patients with advanced phase disease treated… (More)
DOI: 10.1080/10428194.2017.1397666

Topics

Cite this paper

@article{Ruggiu2017AzacytidineIC, title={Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.}, author={Mathilde Ruggiu and Florence Oberkampf and David Ghez and Pascale Cony-Makhoul and Florence Beckeriche and Isabelle Cano and Anne Laure Taksin and Omar Benbrahim and St{\'e}phanie Ghez and Hassan Farhat and Sophie Rigaudeau and No{\'e}mie de Gunzburg and D. L{\'o}pez de Lara and Christine Terr{\'e} and Victoria Raggueneau and Isabel Tena Garc{\'i}a and Marc Spentchian and St{\'e}phane de Botton and Philippe Rousselot}, journal={Leukemia & lymphoma}, year={2017}, pages={1-7} }